ASTRAZENECA ORD USD0.25

Symbol: AZN

This security went ex-dividend on 22/02/2024. Pay date is 25/03/2024

Streaming is not available when market closed. Some prices may be as at close of business from the previous working day.

Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.

Invest in this share within an ISA, JISA, SIPP or Investment Account

Overview

Core Data
Latest Dividend Information

Ex-Dividend Date 22 Feb 2024
Pay Date 25 Mar 2024
Total Dividends - Year to Date227.8
Dividend Yield (%)2.2599

Historical Data & Ratios

Avg Volume Over 10 Days3.4935
Market Cap (M)157868.6000
Price/Earnings (PE)33.4162
Earnings Per Share301.65
Revenue Per Share23.2434
Return on Equity %15.6340

1 Month Performance Chart

One Month Chart

Broker View
Data shown is based on the past 75 days of broker views.

ActionBrokers

Strong Buy7

Buy14

Neutral5

Sell0

Strong Sell2

Brokers 7 14 5 0 2
Consensus

ConsensusBuy

Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.

Cost and Charges Information

This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product

Account Type

  • Investment Account
  • Stocks & Shares ISA
  • SIPP

Annual charges

These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate

Cost Category % of Investment lump sum costs
Our annual fee

Our annual fee

Includes our platform fee at 0.35% per annum for Funds (up to £250,000) and Stocks & Shares (min £24 max £240), plus SIPP administration fee (if applicable, only charged if <£30,000 held) - see here
0.35%
Dealing charges

Dealing charges

Any one-off commission charges associated with investing. Note that government taxes and levies are not included
N/A
Product provider costs

Product provider costs

Product provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs
N/A N/A
Total (£)

Total (£)

Costs per annum displayed in monetary value
Total (%)

Total (%)

Costs per annum displayed as a percentage of investment value

Cumulative effect of charges on your investment's return

This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges

lump sum invested with an assumed growth rate of 1 year years
What you might get back at  with no charges applied

What you might get back at  with no charges applied

These are the illustrative values of a  investment after growth and no costs applied at the end of the defined period
Annual charges

Annual charges

These are the annual costs based on an initial investment amount of assuming a net zero growth rate
Effect of charges on return (%)

Effect of charges on return (%)

These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate
Effect of charges on return (£)

Effect of charges on return (£)

These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate
What you might get back at with charges applied

What you might get back at with charges applied

These are the illustrative values of a investment after growth and costs at the end of the defined period

This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use

Charts

  • Chart Options

    Select Timeframe Add a sector as a comparator Add an index as a comparator Add a share as a comparator

      Add a moving average as a comparator Add a lower indicator as a comparator Chart Style Current Comparators

      Company

      Business Summary

      AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.

      Financial Summary

      BRIEF: For the fiscal year ended 31 December 2023, AstraZeneca plc revenues increased 3% to $45.81B. Net income increased 81% to $5.96B. Revenues reflect Product sales increase of 2% to $43.79B. Net income benefited from acquisition-related costs and credits decrease of 97% to $119M (expense), Selling, General - Intangible amortiz decrease of 6% to $3.87B (expense), Restructuring decrease of 49% to $207M (expense).

      Financials


      Income Statement - All values are in GBP (M).

      Year Ending

      31/12/2023

      31/12/2022

      31/12/2021

      31/12/2020

      31/12/2019

      31/12/2018

      Total Revenue 45,811.00 44,351.00 37,417.00 26,617.00 24,384.00 22,090.00
      Gross profit 37,743.00 35,702.00 27,875.00 21,347.00 19,560.00 17,844.00
      Operating Profit/Loss 8,193.00 3,757.00 1,056.00 5,162.00 2,924.00 3,387.00
      Profit Before Tax 6,899.00 2,501.00 -265.00 3,916.00 1,548.00 1,993.00
      Profit After Tax 5,961.00 3,293.00 115.00 3,144.00 1,227.00 2,050.00
      Equity Holders of Parent Company 5,955.00 3,288.00 112.00 3,196.00 1,335.00 2,155.00
      Minority Interest 17.00 16.00 16.00 68.00 1,577.00 1,681.00


      Balance Sheet - All values are in GBP (M).

      Year Ending

      31/12/2023

      31/12/2022

      31/12/2021

      31/12/2020

      31/12/2019

      31/12/2018

      Total Non-Current Assets 76,065.00 73,890.00 79,119.00 47,185.00 45,814.00 45,060.00
      Total Current Assets 25,054.00 22,593.00 26,244.00 19,544.00 15,563.00 15,591.00
      Total Assets 101,119.00 96,483.00 105,363.00 66,729.00 61,377.00 60,651.00
      Total Liabilities 61,953.00 59,425.00 66,076.00 51,091.00 46,781.00 46,607.00
      Total Net Assets 39,166.00 37,058.00 39,287.00 15,638.00 14,596.00 14,044.00
      Shareholders Funds 39,143.00 37,037.00 39,268.00 15,622.00 13,127.00 12,468.00
      Minority Interests 17.00 16.00 16.00 68.00 1,577.00 1,681.00
      Total Equity 39,166.00 37,058.00 39,287.00 15,638.00 14,596.00 14,044.00

      Outlook

      Broker View
      Data shown is based on the past 75 days of broker views.

      ActionBrokers

      Strong Buy7

      Buy14

      Neutral5

      Sell0

      Strong Sell2

      Brokers 7 14 5 0 2
      Consensus

      ConsensusBuy

      Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.

      © 2022 Refinitiv, an LSEG business. All rights reserved.

      Forecasts

      Year 2024 2025 2026
      Revenue £50,646.60mn £54,514.50mn £57,373.90mn
      Pre-tax-Profit £15,768.90mn £18,073.40mn £19,451.10mn
      EPS £6.46p £7.20p £8.03p
      EPS Growth 112.98% 11.44% 11.62%
      P/E 15.58 14.01 12.57
      PEG Ratio 0.14 1.23 1.08
      Dividend 245.94p 257.48p 263.04p
      Yield 0.00% 0.00% 0.00%

      Upgrades & Downgrades (Latest)

      DateBrokerRecommendationPriceOld TargetNew TargetChange
      27th Feb 2024DeutscheReiteration10328p0p9500pSell
      20th Feb 2024JP Morgan CazenoveReiteration10204p0p12500pOverweight
      19th Feb 2024Berenberg BankReiteration10418p125p120pBuy
      16th Feb 2024JefferiesReiteration10094p11000p11000pHold
      12th Feb 2024UBSReiteration9501p10700p9900pSell
      12th Feb 2024BarclaysReiteration9501p135p125pOutperform
      12th Feb 2024BMO Capital MarketsReiteration9501p0p0pOutperform
      12th Feb 2024StifelReiteration9501p125p120pBuy
      8th Feb 2024Shore CapitalReiteration9823p0p0pBuy
      28th Nov 2023CitigroupReiteration9900p0p0pBuy

      Time & Sales

      All prices are in GBX and times are in GMT. Last 20 trades shown. Trade type is estimated and should be treated as indicative only.

      Date Time Price Volume Type
      4 Mar 2024 18:58 10,056 0 Sell
      4 Mar 2024 18:58 10,056 0 Sell
      4 Mar 2024 18:58 10,056 0 Sell
      4 Mar 2024 18:49 10,052 0 Sell
      4 Mar 2024 18:49 10,052 0 Sell
      4 Mar 2024 18:49 10,052 0 Sell
      4 Mar 2024 18:46 10,056 0 Sell
      4 Mar 2024 18:36 10,046 1 Sell
      4 Mar 2024 18:34 10,050 1 Sell
      4 Mar 2024 18:34 10,052 0 Sell
      4 Mar 2024 18:34 10,052 0 Sell
      4 Mar 2024 18:33 10,052 0 Sell
      4 Mar 2024 18:32 10,048 0 Sell
      4 Mar 2024 18:32 10,048 0 Sell
      4 Mar 2024 18:32 10,048 0 Sell
      4 Mar 2024 18:29 10,034 1 Sell
      4 Mar 2024 18:24 10,024 1 Sell
      4 Mar 2024 18:06 10,042.976 2,429 Sell
      4 Mar 2024 18:04 10,029.544 5,547 Sell
      4 Mar 2024 18:02 10,045.994 12,513 Sell

      Selected data supplied by Thomson Reuters ©  View restrictions.

      VIEW ALL MARKET NEWS

      Investment involves risk. You may get back less than invested.